Clinical trials
Mantle Cell Lymphoma clinical trials
Below are recruiting mantle cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05635162RecruitingPhase 2
Zanubrutinib plus rituximab for slow-growing mantle cell lymphoma
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
DerbyAges 18 years+ - NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
Westwood, KansasAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT05833763RecruitingPhase 2
Glosfitamab plus pirtobrutinib for mantle cell lymphoma after BTK drugs
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Parkville, VictoriaAges 18 years+ - NCT05868395RecruitingPhase 2
Treating relapsed mantle cell lymphoma with three drug combination
This Phase 2 study tests how well polatuzumab combined with bendamustine and rituximab works for mantle cell lymphoma that has come back or not responded. It may help shrink tumors and improve disease control, especially after prior treatment with ibrutinib.
ViennaAges 18–100 - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT05910801RecruitingPhase 2
Tafasitamab plus lenalidomide and venetoclax for relapsed lymphoma
This Phase 2 trial studies tafasitamab together with lenalidomide and venetoclax in people with mantle cell lymphoma (MCL) that has come back or did not respond to prior treatment. It may help shrink the lymphoma and improve disease control when standard options have not worked.
Rochester, MinnesotaAges 18 years+ - NCT06022029RecruitingPhase 1
Study of injected ONM-501 alone or with cemiplimab for advanced cancers
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06026319RecruitingPhase 1
CAR T cells targeting CD79b and CD19 for non-Hodgkin lymphoma
This trial tests a new type of CAR T-cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It's for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments.
Boston, MassachusettsAges 18 years+ - NCT06029309RecruitingPhase 1/Phase 2
Zanubrutinib and tafasitamab for mantle cell lymphoma
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Miami, FloridaAges 18 years+ - NCT06043011Recruiting
Registry for non-Hodgkin lymphoma patients on systemic therapy
This registry tracks people with non-Hodgkin lymphoma who are starting a new line of systemic therapy. It collects information to better understand how treatments work in real life, and optionally asks you to fill out surveys about your symptoms and quality of life.
Freiburg im BreisgauAges 18 years+ - NCT06045910RecruitingPhase 1/Phase 2
A study of ALETA-001 for certain B-cell blood cancers
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
BirminghamAges 16 years+ - NCT06054776RecruitingPhase 2
Acalabrutinib, obinutuzumab, and glofitamab for mantle cell lymphoma
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Duarte, CaliforniaAges 18 years+ - NCT06136351RecruitingPhase 2
Zanubrutinib with chemo for mantle cell lymphoma
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (bendamustine and rituximab) for people newly diagnosed with mantle cell lymphoma. It is designed for older adults, those with certain genetic changes (TP53), or those who cannot tolerate standard chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06151730Recruiting
Managing blood pressure and heart risks during BTKi treatment
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Rochester, MinnesotaAges Any age - NCT06191887RecruitingPhase 1
BAFFR-targeting CAR-T cells for relapsed B-cell blood cancers
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
Jacksonville, FloridaAges 18 years+ - NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B-cell cancers
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Calgary, AlbertaAges 1 year+ - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06263491RecruitingPhase 2
Pirtobrutinib and Rituximab for Low/Medium Risk MCL
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
Houston, TexasAges 18 years+ - NCT06313957RecruitingPhase 1
Study of LUCAR-20SP for relapsed B-cell lymphoma
This trial tests a new treatment called LUCAR-20SP for people with certain types of B-cell lymphoma that have come back or not responded to prior therapy. The drug is a type of CAR-T therapy that targets the CD20 protein on lymphoma cells.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06558604RecruitingPhase 2
Study of glofitamab with venetoclax for high-risk mantle cell lymphoma
This trial tests a new combination of drugs (glofitamab plus venetoclax, with or without zanubrutinib) for people with mantle cell lymphoma that is either newly diagnosed with high risk features, or has come back or not responded to earlier treatments. The goal is to see if these targeted therapies can improve outcomes.
BrugesAges 18–79 - NCT06339255Recruiting
Observational study on CAR-T therapy for lymphoma
This study observes patients with certain lymphomas who are already eligible for standard CAR-T cell therapy in Italy. It aims to gather real-world information about how these treatments work.
MilanAges 18 years+ - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06341556RecruitingPhase 2
Study of zanubrutinib as maintenance therapy for mantle cell lymphoma
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mantle cell lymphoma?
- Yes. Clin2 currently lists 161 recruiting mantle cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mantle cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mantle cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.